Sandoz announced that its biosimilar application for Neulasta® (pegfilgrastim) has been accepted for regulatory review by the European Medicines Agency (“EMA”). According to Sandoz, “[t]he comprehensive data package, submitted as part of the Marketing Authorization Application, includes analytical, preclinical and clinical data and strongly demonstrates that the biosimilar pegfilgrastim matches the reference medicine in terms
More Posts
PTAB Institutes Review on Four Celltrion Petitions Targeting Herceptin®
PTAB Denies Institution of Rituxan® IPRs Because Petitioner Failed to Establish Certain References Were Publicly Available
Pfizer Seeks Inter Partes Review of Rituximab Patents
AbbVie and Amgen Settle Humira Patent Litigation
Pfizer Files Another IPR Against Genentech’s ʼ441 Patent
Sanofi, Genzyme, and Regeneron Voluntarily Dismiss Dupixent® (Dupilumab) Declaratory Judgment Suit in Massachusetts
Immunex Files Patent Infringement Suit Over Dupixent® (Dupilumab) and Seeks to Dismiss or Transfer Sanofi and Regeneron’s Prior DJ Complaint
Sanofi and Regeneron Follow Declaratory Judgment Complaint with an IPR Petition as FDA Approves Dupixent® (dupilumab)
Sanofi and Regeneron Seek Declaratory Judgment that Dupixent® (Dupilumab) Does Not Infringe Amgen’s Patent
Subscribe: Subscribe via RSS
Blogs
Firm/Org